Dermato-oncology
This year, we are celebrating our inaugural touchDERMATOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform dermatology in the years to come. Representing a diverse range of expertise from across the globe, these highly accomplished clinicians are among the brightest minds shaping the future of dermatology. We had the pleasure of learning about their unique career journeys, motivations, and the inspirations that have guided their paths. They also shared their perspectives on the most exciting developments in dermatology today, along with their hopes for the future of the field. Congratulations to all our touchDERMATOLOGY Future Leaders, and thank you for sharing your stories, insights and ambitions with us.
Dr Tashmeeta Ahad is helping to push the boundaries of modern dermatology. Based in Vancouver, she is a Clinical Assistant Professor at the University of British Columbia and a clinician-scientist at the Photomedicine Institute, where her work spans photosensitivity disorders, laser and phototherapy, and innovative optical biopsy techniques for skin cancer monitoring. In this Future Leader 2025 Q&A, Dr Ahad shares how her global training journey, early mentors, and the visual complexity of dermatology have shaped her career—and why imaging technologies are opening new possibilities for patient care.
From an unexpected start to becoming a dual specialist in dermatology and dermatopathology, Dr Jonathan Ho is helping redefine skin health in the Caribbean. Based in Kingston, Jamaica, he’s combining clinical care, research, and education to improve outcomes for patients with autoimmune, malignant and complex skin conditions. In this Future Leader 2025 Q&A, Dr Ho shares the pivotal moments that shaped his career, his passion for mentorship, and how he’s building a meaningful path in academic dermatology.
The International Society of Dermatology (ISD) stands at the forefront of advancing global skin health through education, collaboration and outreach.1 Established with a mission to bridge disparities in dermatological care worldwide, the ISD has become a vital hub for connecting ...
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The International Society of Dermatology (ISD) stands at the forefront of advancing global skin health through education, collaboration and outreach.1 Established with a mission to bridge disparities in dermatological care worldwide, the ISD has become a vital hub for connecting ...
At ASCO 2024 in Chicago, some exciting breakthroughs in melanoma research were revealed. Researchers from around the world presented innovative studies and cutting-edge treatments that could significantly impact melanoma care. We have selected some of the most exciting data to highlight that could impact patient outcomes in the future.
A recent study published in Nature’s Scientific Reports has found a significant association between rosacea and malignant melanoma in Caucasian populations.
Non-melanoma skin cancer (NMSC) is responsible for a higher worldwide mortality rate compared to melanoma, a more severe type of skin cancer. A comprehensive analysis of global skin cancer incidence and mortality assessed global skin cancer epidemiology, emphasizing incidence, mortality, risk profiles, and dermatologist density’s impact. touchDERMATOLOGY caught up with Prof. Thierry Passeron (University Hospital of Nice, Nice, France) to discuss the key outcomes and the likely impact the findings will have on clinical practice. The abstract 'A comprehensive analysis of global skin cancer incidence and mortality with a focus on dermatologist density and population risk factors' (Abstract N°: P1519) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What is the global burden of non-melanoma skin cancer? (0:11) What were the key outcomes from your study of WHO International Agency for Research on Cancer? (0:38) What impact will these findings have on clinical practice? (1:58) Disclosures: Thierry Passeron has been a consultant for Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma; received grant/research support from Abbvie, Almirall, BMS, Celgene, Incyte, Isocell, LEO Pharma, Lilly; and has received honorarium from Almirall, Abbvie, Amgen, Astellas, BMS, Celgene, Galderma, GSK, Incyte, Isocell, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Sanofi-Genzyme, SUN pharma, UCB pharma. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.Â
Brentuximab vedotin, an antibody–drug conjugate, was approved for the treatment of cutaneous T-cell lymphoma (CTCL) in Europe in 2017. In this touchDERMATOLOGY interview, we spoke with Prof. Adam Reich (University of Medicine, Wroclaw, Poland) to discuss the rationale and findings from his observational open-label study of brentuximab vedotin for CTCLs, assessing the real-world efficacy and safety of the ADC in Poland. The abstract ‘Real-world outcomes of brentuximab vedotin treatment in patients with CD30-expressing cutaneous T-cell lymphoma: 24‑week interim analysis of a prospective, multicenter, observational study in Poland.’ (Abstract N°: 6587) was presented at EADV 2023, Berlin, 11-14 October 2023 #EADVCongress. Questions What challenges are associated with treating advanced cutaneous T-cell lymphomas (CTCLs)? (0:21) Could you give us a brief overview of the findings from the phase 3 ALCANZA trial? (0:54) What were the aims and design of the observational open-label study you presented at EADV? (1:55) What were the real-world efficacy and safety findings from your study? (2:37) How will these insights optimise the use of brentuximab vedotin for CTCLs? (3:19) Disclosures: Adam Reich discloses receiving grant/research support from Abbvie, Anaptys, BMS, Dice, Eli Lilly, Galderma, Incyte, Jannsen, Medac, Novartis, Pfizer, Regeneron, Trevi Therapeutics, and UCB; serving on advisory boards for Abbvie, Galderma, Leo Pharma, Sanofi, Novartis, and Eli Lilly. Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch. Filmed in coverage of the EADV Annual Meeting. This content was developed by Touch Medical Media and is not affiliated with the  European Academy of Dermatology & Venereology  (EADV) or the congress.Â
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
